Alterity Therapeutics (ATHE) Non Operating Interest Expenses (2013 - 2025)

Alterity Therapeutics has reported Non Operating Interest Expenses for 8 years, with the latest figure at $195282.0 in Q4 2025.

• On a quarterly basis, Non Operating Interest Expenses rose 11.86% year-over-year to $195282.0 in Q4 2025; TTM through Dec 2025 was $850808.2, a 4.63% decrease from a year earlier, with the FY2024 full-year figure at $445644.9, down 7.61% from the prior year.
• Non Operating Interest Expenses was $195282.0 for Q4 2025 at Alterity Therapeutics, up from $174574.4 in the prior quarter.
• The five-year high for Non Operating Interest Expenses was $247860.8 in Q4 2022, with the low at $174574.4 in Q4 2024.
• Average Non Operating Interest Expenses over 5 years is $217484.8, with a median of $233091.0 recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Non Operating Interest Expenses fell 25.1% in 2024, then advanced 11.86% in 2025.
• Over 5 years, Non Operating Interest Expenses stood at $236615.6 in 2021, then grew by 4.75% to $247860.8 in 2022, then slipped by 5.96% to $233091.0 in 2023, then dropped by 25.1% to $174574.4 in 2024, then climbed by 11.86% to $195282.0 in 2025.
• The last three Non Operating Interest Expenses figures came in at $195282.0 (Q4 2025), $174574.4 (Q4 2024), and $233091.0 (Q4 2023), per Business Quant data.